Drug regulatory measures continue to strengthen, hospitals to purchase high-priced drugs or become increasingly difficult

"
Pharmaceutical Network Policy and" Recently, Shanghai issued "Strengthening the drug network open bargaining procurement supervision of tips." The document said that the drug network to further strengthen the supervision of open bargaining procurement, and the bargaining super yellow line of drugs into the scope of key supervisionit is understood that in October 2018, Shanghai for the implementation of the drug network open bargaining to develop a "red, yellow, green" three-line rulesIn October 2019, Shanghai began to officially implement the public bargaining procurement of drug hook-up network, flow labels and shortage of drugs can apply for the Shanghai Sunshine procurement platformAfter hanging the net, the hospital can negotiate with the pharmaceutical companies and make their own purchasesThe purchasing platform also set up a green line reference, yellow line reminder and red line blocktoforth to make a bargain ingenuity reminder, the green line refers to the drug original bid price or hanging net price, Shanghai bargaining results to low price sand with the drug 15 provinces and cities to low purchase price of the three low priceThe yellow line refers to the original bid price or hanging net price, the Ministry of Human And Social Affairs drug coding standard library of the same code d'etat of the drug varieties in the city's medical institutions to negotiate the results to high prices, the original research drugs or reference preparation prices of a certain proportion, the mainstream varieties pricefrom the Shanghai issue of tips, as long as not lower prices, hospital bargaining results will be focused on monitoringIn this regard, the industry believes that in publicity, interviews and other measures to deter, this will urge hospitals and pharmaceutical companies to negotiate prices, directly to low-cost negotiations, a wave of drugs or in hospitals will usher in a big price cutin fact, in recent years, with the increasing reform of medicine, the state has begun to more and more strict supervision of the procurement of medicines in medical institutionsOn March 5 this year, the state issued the Opinions on Deepening the Reform of the Health Care System, which clearly proposed to improve the strict and strong fund supervision system and innovate the way of fund supervisionEstablish a normal mechanism for supervision and inspection, and implement dynamic intelligent monitoring of big dataWe will improve the monitoring mechanism for medical services, establish a mandatory disclosure system for information, and disclose information such as medical expenses and expense structure to the public in accordance with the lawlast April, the National Health and Health Commission's Drug Policy and Essential Medicines System Division issued the "National Health And Wellness Commission notice on drug use monitoring and comprehensive clinical evaluation", also decided to monitor all drugs equipped with the use of drugs nationwideat the moment, driven by policies, and not only Shanghai is starting to buy high-priced drugs for hospitalsOn April 23, the Hebei Provincial Medical Insurance Bureau issued a document entitled "Notice on the establishment of an abnormal growth warning system for the abnormal growth of medical expenses indicators in fixed-point medical institutions." It has also been made clear that the medical care costs will be monitored in real time through the medical regulatory big data analysis systemThe document reminds that after the reminder, the medical cost indicators for 2 consecutive months still have abnormal growth, will also start the interview reminder mechanismin general, it is becoming harder for hospitals to procure high-priced drugs under big data monitoringThis time, the implementation of Shanghai drug hanging network open bargaining procurement supervision, will undoubtedly make many drugs survival difficulty further increased, especially for the hope that the network open bargaining way to enter the Shanghai market new varieties, will be a testBut at the same time, lower drug prices will also benefit a large number of patients and reduce medical expensesTime and market feedback will be needed as to whether this model will be rolled out nationwide in the future.